1. Introduction {#sec1-1}
===============

Agitation, excessive motor and/or verbal activity, characterized by excitement, restlessness, and psychic and motor tension, is common in patients with schizophrenia. Agitation can escalate into aggressive behavior leading to high risk of injury for patients, relatives or staff.^\[[@ref1]\]^ Furthermore, agitation increases the frequency of patient emergency department visits with further negative consequences.^\[[@ref4]\]^

In order to minimize the risk posed to self or others, agitated patients should be managed, first and preferably by non-pharmacological interventions such as environmental and behavioral modification, and secondly by pharmacological agents.^\[[@ref3]\]^ However, in most cases the management of agitation largely depends on pharmacological agents,^\[[@ref6]\]^ mainly benzodiazepines and antipsychotics (APs) with their well-known adverse effects particularly if they are administered repeatedly.^\[[@ref1],[@ref3]\]^

Electroconvulsive therapy (ECT) is a fast, effective and safe treatment for a variety of psychiatric disorders.^\[[@ref7]\]^ Use of ECT for acute or even prolonged agitation has received scant attention in contemporary literature and it appears that ECT is hardly ever used for this purpose in developed countries. However, ECT remains an option for agitation or aggression in China and developing countries.^\[[@ref8]\]^ There have been a number of studies published in China, including randomized controlled trials (RCTs)^\[[@ref9]\]^ to compare the efficacy of ECT alone or the ECT-AP combinations to AP monotherapy with conflicting results.

To the best of our knowledge, no systematic review or meta-analysis of ECT treatment for agitation in schizophrenia has been published. This was the impetus for this meta-analysis concerning the efficacy and safety of ECT treatment for agitation in schizophrenia.

2. Methods {#sec1-2}
==========

2.1 Selection of studies {#sec2-1}
------------------------

According to PICOS acronym, the inclusion criteria were: Participants (P): adult schizophrenia patients (≥18 years) with agitation. Intervention (I): ECT alone and ECT-AP combination. Comparison (C): AP monotherapy. Outcomes (O): primary outcomes were the improvement of agitation related outcomes at last-observation-carried-forward (LOCF) study endpoint measured by the Positive and Negative Syndrome Scale (PANSS),^\[[@ref16]\]^ Brief Psychiatric Rating Scale (BPRS),^\[[@ref17]\]^ and any other scales or sub-scales or item for agitation: 1) total psychopathology scores, 2) the excitement sub-scores, and 3) the agitation sub-scores. Key secondary outcomes included early symptomatic improvement (at 1, 3, 7, and 14 days), rate of all-cause discontinuation and patient-reported adverse events. Study design (S): RCT with available data. The exclusion criteria were case series, non-randomized studies, and non-original research (reviews and meta-analyses).

2.2 Search strategy {#sec2-2}
-------------------

English databases (PubMed, PsycINFO, and Cochrane Library) and Chinese databases (WanFang Database, Chinese Biomedical Database and China Journal Net) were searched, from their inception until Feb 3, 2017 using the following search terms: (1) English databases: (ECT OR Electric Convulsive Therap\* OR Therap\*, Electric Convulsive OR Electroshock Therap\* OR Convulsive Therap\*, Electric) OR Electroconvulsive Therapy OR Electroconvulsive Therapies OR Therap\*, Electroconvulsive OR Electric Shock Therap\* OR Shock Therap\*, Electric OR Therap\*, Electric Shock OR Therap\*, Electroshock) AND (schizoaffective disorder OR schizophreniform OR Schizophrenic Disorder OR Disorder, Schizophrenic OR Schizophrenic Disorders OR Schizophrenia OR Dementia Praecox) AND (agitation OR exciting OR aggression); (2) Chinese databases: (电休克 OR 电抽搐 OR ECT OR MECT OR 电痉挛) AND (激越 OR 攻击 OR 兴奋 AND 随机 AND (精神分裂症 OR 精神分裂). The search was supplemented by using the "related article" function. Hand-searched reference lists from relevant review articles for additional studies were hand-searched and authors contacted for unpublished data.

2.3 Data extraction {#sec2-3}
-------------------

Two independent evaluators (GXJ and ZW) selected studies, extracted data, conducted quality assessment and data synthesis. Any inconsistencies were resolved by discussion to reach consensus or involvement of a third reviewer (XYT).

2.4 Data synthesis and statistical analyses {#sec2-4}
-------------------------------------------

Clinical outcomes were based on intent-to-treat (ITT) analysis, if available. The meta-analysis was performed using Review Manager (version 5.3) according to the recommendations of the Cochrane Collaboration.^\[[@ref18]\]^ To combine studies, the random effects model^\[[@ref19]\]^ was used in all cases. For continuous data and dichotomous data, weighted mean differences (WMDs) associated with their 95% confidence intervals (CIs) and risk ratio (RR) ±95% CIs were calculated, respectively. We reported the number-needed-to-treat (NNT) or number-needed-to-harm (NNH) calculated by dividing 1 by the risk difference as soon as RR was significant. One study^\[[@ref11]\]^ from the 'ECT alone' group had three study arms. According to the methodology of prior meta-analysis,^\[[@ref20]\]^ we should include each of the 2 ECT arms separately in one RCT^\[[@ref11]\]^ with 3 treatment arms. Furthermore, the APs monotherapy arm was included twice in the analysis, but half of all patients were randomized to each AP arm in order not to inflate the number of patients in the APs monotherapy arm.

In case of I^2^≥50% for the effect of primary outcome on the PANSS total score, a sensitive analysis was conducted by excluding one outlying study^\[[@ref15]\]^ with an outlying effect size (ES) of less than -1.24 (i.e., more than 1.24 standard deviation superiority of ECT-AP combination) in the 'ECT-AP combination' group. Furthermore, subgroup and meta-regression analyses were conducted to detect the sources of heterogeneity, if possible. Publication bias was assessed using funnel plots and Egger's test.^\[[@ref21]\]^ All statistical differences were considered significant when *p*\<0.05.

2.5 Assessment of study quality {#sec2-5}
-------------------------------

The Cochrane risk of bias^\[[@ref18]\]^ was used to assess the quality of each study. Furthermore, the quality of each study was also assessed with the Jadad scale that assesses study quality on a 5-point scale along the following five domains: "randomization," "double blinding," "description withdrawals and dropouts," "generation of random numbers," and "allocation concealment".^\[[@ref22]\]^ The criteria of high and low quality were defined as Jadad score ≥4 and \<4, respectively.

2.6 Clinical evidence recommendation {#sec2-6}
------------------------------------

The grading of recommendations assessment, development, and evaluation (GRADE) system^\[[@ref23]\]^ was used to judge the quality of clinical evidence recommendations of the meta-analytic results of ECT for agitation in schizophrenia.

3. Results {#sec1-3}
==========

3.1 Results of the search {#sec2-7}
-------------------------

Altogether 133 potentially relevant articles from English (n=96) and Chinese databases (n=37) were identified; duplication excluded 14 studies. Of the remaining 119 entries, 112 were determined to be irrelevant after review of the titles and abstracts, a further 7 were removed on the basis of full text review. Finally, 7 RCTs with 8 treatment arms met the selection criteria for the meta-analysis ([Figure 1](#fig001){ref-type="fig"}).

3.2 The characteristics of included studies {#sec2-8}
-------------------------------------------

The seven RCTs lasted an average of 4.3(3.1) weeks (range: 2-8 weeks; median: 2 weeks). The total number of participants in all the studies was 480 (range: 30-100, median: 60). All the RCTs that met our inclusion and exclusion criteria were thus included in the meta-analysis had been conducted in China. Aggregating data across all the reviewed trials: there were 240 patients in ECT monotherapy vs. AP monotherapy (n=135 vs. n=105) comparison and 240 patients in the ECT-AP vs. AP monotherapy (n=120 vs. n=120) comparison ([Table 1](#table001){ref-type="table"}); patients were on average 34.3(4.5) years old (range: 31.9-43.5 years; median: 32.5 years) in 6 RCTs with available data; 57.6(14.2)% were males (range: 40.0%-80.0%; median: 56.7%); and the mean illness duration with available data (6 RCTs) was 2.7(2.7) years (range: 0.02-6.1 years; median: 2.2 years).

3.3 Assessment of risk of bias and quality assessment {#sec2-9}
-----------------------------------------------------

The Cochrane risk of bias was presented in [Table 2](#table002){ref-type="table"}. 85.7% (6/7) RCTs only mentioned "random" assignment, lacking a detailed description of the method of randomizing and thus were rated as unclear. However, only one RCT^\[[@ref13]\]^ using random assignment according to the random number table was rated as low risk. Given that all included studies were open label, the allocation bias, performance bias, and detection bias were rated as high risk. None of the included RCTs presented the study registration materials, which limited us to determine whether or not there was selective reporting (i.e., reporting bias). Furthermore, it was impossible to judge the other types of biases (e.g., drug company sponsorship of the study) due to lack of available evidence. Overall, 7 included RCTs suffered from high risk of bias and were considered as relatively low-quality studies. The Jadad score was 2.0(0.6) (range=1-3, median=2) ([Table 1](#table001){ref-type="table"}). All RCTs were rated as low quality (Jadad score \< 4). Due to pooling of data, less than 3 RCTs with 4 treatment arms were in all forest plots, thus funnel plot analysis to show the presence of risk of publication bias could not be conducted.

3.4 The improvement of agitation related outcomes {#sec2-10}
-------------------------------------------------

There were differences between the ECT alone vs AP (4 RCTs with 5 treatment arms) and ECT-AP vs AP (3 RCTs) groups. Moreover, the improvement of agitation related outcomes were measured using PANSS in all included RCTs.

ECT alone vs AP: ECT alone was superior to AP monotherapy with respect to PANSS total score (WMD=-7.13, (95%CI: -11.99, -2.27), *I*^[@ref2]^=0%, *p*=0.004, [Figure 2](#fig002){ref-type="fig"}) and excitement sub-score (WMD=-1.97, (95%CI: -2.87, -1.08), *I*^[@ref2]^=0%, *p*\<0.0001, [Figure 2](#fig002){ref-type="fig"}), but not in the agitation sub-score (WMD=-0.90, p=0.38); ECT alone was superior to AP monotherapy in PANSS total score at 14 days (WMD:-7.13 (95%CI:-11.99, -2.27), *p*=0.004; *I*^[@ref2]^=0%, [Supplemental Figure 1](#supp001){ref-type="fig"}), but not at 1 and 7 days (WMD:-5.23 to -7.13 (95%CI:-16.86, 4.25), *p*=0.06 to 0.24; *I*^[@ref2]^=0% to 77%, [Supplemental Figure 1](#supp001){ref-type="fig"}). Furthermore, subgroup and meta-regression analyses could not be performed due to the limited number of RCTs.

Furthermore, ECT alone was superior to AP monotherapy in PANSS excitement sub-score at 7 and 14 days (WMD:-1.97 to -1.92 (95%CI:-3.14, -0.71), *p*=0.002 to 0.0001; *I*^[@ref2]^=0%, [Supplemental Figure 2](#supp002){ref-type="fig"}), but not at 1 day after ECT treatment (WMD:-1.92 (95%CI:- 4.00, 0.17), *p*=0.07; *I*^[@ref2]^=35%, [Supplemental Figure 2](#supp002){ref-type="fig"}). Among the ECT alone studies one RCT^\[[@ref10]\]^ used Clinical Global Impression (CGI) and found an advantageous improvement of psychiatric symptoms in the ECT group at 7 and 14 days.

ECT plus AP vs AP: Regarding the PANSS total score, the ECT-AP combination was superior to AP monotherapy (WMD=-10.40, (95%CI: -19.67, -1.12), *I*^[@ref2]^=93%, *p*=0.03, [Figure 3](#fig003){ref-type="fig"}), but not in the excitement and agitation sub-scores (WMD=-1.06 to -1.34, *p*=0.33 to 0.37). The significant difference between the two groups in the PANSS total score disappeared after one outlying study^\[[@ref15]\]^ was removed (WMD:-4.23 (95%CI:-8.89, 0.43), *p*=0.08; *I*^[@ref2]^=76%). Furthermore, subgroup and meta-regression analyses could not be performed due to the limited number of RCTs.

Furthermore, adding ECT to AP was superior to AP monotherapy at 7 days for the PANSS total score (WMD=-5.01, (95%CI: -9.37, -0.66), *I*^[@ref2]^=14%, *p*=0.02, [Figure 4](#fig004){ref-type="fig"}), but not to PANSS total score (*p*=0.15), excitement (*p*=0.35) and agitation sub-scores (*p*=0.44) at 14 days ([Figures 4](#fig004){ref-type="fig"}).

3.5 Side effects and discontinuation rate {#sec2-11}
-----------------------------------------

The Treatment Emergent Symptom Scale (TESS) was generally used to assess adverse drug reactions (ADRs) in these RCTs however such data were not available in 1 RCT ([Table 1](#table001){ref-type="table"}). None of the included RCTs reported the rate or cause of treatment discontinuation.

ECT alone vs APs: Headache (p=0.0001, NNH=3, 95%CI=2-4) was the only ADRs more frequent in the ECT alone group compared to AP monotherapy ([Supplemental Figure 3](#supp003){ref-type="fig"}). There was significantly less akathisia (p=0.02, NNH=8, 95%CI=5-17) and electrocardiogram changes (p=0.05) with borderline significance in the ECT alone group compared to the AP group. Meta-analysis of uroclepsia, weight gain, upper respiratory infections, tremor, dry mouth, insomnia, and electroencephalography changes did not differ between the groups ([Supplemental Figure 3](#supp003){ref-type="fig"}).

ECT plus AP vs AP: Only two RCTs ^\[[@ref9],[@ref13]\]^ reported the ADRs without meta-analyzable data.

3.6 Clinical evidence recommendation {#sec2-12}
------------------------------------

Clinical evidence recommendation of the main meta-analytic outcomes based on the GRADE approach showed some limitations of risk of bias, inconsistency and publishing bias, and no obvious indirectness or imprecision. According to the above assessments, the quality of evidence of 8 outcomes presented in [Table 3](#table003){ref-type="table"} and ranged from ''very low'' (37.5%), "low" (50%), to ''high'' (12.5%).

4. Discussion {#sec1-4}
=============

4.1 Main findings {#sec2-13}
-----------------

Despite a systematic literature search in both English and Chinese-language databases, we only identified 7 RCTs with 8 treatment arms that examined the efficacy and safety of using ECT for the treatment of agitation in 480 patients with schizophrenia who are currently using APs. All included RCTs were open label and the assessment of outcomes was not blinded in all trials. Furthermore, the quality of all included RCTs was rated as 'low quality' based on Jadad scale. Overall, the results suggest that both ECT alone and the ECT-AP combination over 2 to 8 weeks had superior efficacy to AP monotherapy regarding the reduction in PANSS total score, but not in the agitation sub-score. ECT and ECT-AP combination were both safe and well tolerated. The reduction in the total PANSS score with ECT alone was superior to AP monotherapy as early as at 1 day with a moderate effect size of -0.52, which increased to a relatively larger effect size of -0.60 after 14 days. The ECT-AP combinations were significantly superior to AP monotherapy with respect to PANSS total score at 7 days with a small effect size of -0.36. However, 35 patients reported headache (38.9% vs. 0% on APs monotherapy, NNH=3), which was significantly more common in the ECT alone group. These adverse effects were transient and mild.^\[[@ref10],[@ref11]\]^

4.2 Limitations {#sec2-14}
---------------

Several limitations need to be acknowledged. First, 7 RCTs (100%) reviewed were rated as low quality and the strength of the evidence for 87.5% outcomes was rated as "very low" or "low" according to the GRADE approach. However, strong recommendations does not necessarily imply high quality evidence and low quality evidence can still result in strong recommendations.^\[[@ref23]\]^ Further, the RCTs were inconsistent in their methodology with respect to sampling and the delivery of ECT and the type and dose of antipsychotic medications. Subgroup analyses and meta-regression cannot be employed to lessen the heterogeneity of primary outcomes. Second, data regarding the cognitive effects of ECT were not systematically assessed in the included studies. In addition, agitation, the target symptom in this study, was evaluated with a single item in the PANSS, rather than with a standardized rating scale. Furthermore, some more variables potentially associated with agitation, such as the quality of care and patients' education, were not assessed in included studies. Third, treatment adherence was not routinely assessed or reported. In particular, the ECT dose-response effects on agitation when used as monotherapy or/and co-treatment in agitation patients with schizophrenia, definitely needs to be more fully evaluated. Finally, all studies were conducted in China thus the findings need to be replicated in other countries.

4.3 Implications {#sec2-15}
----------------

Although this paper included 7 low quality RCTs with small samples and the methodological limitations^\[[@ref23]\]^ identified, the thorough methodology of this meta-analysis included the assessment of quality using the Cochrane risk of bias,^\[[@ref18]\]^ Jadad scale^\[[@ref22]\]^, and GRADE system.^\[[@ref23]\]^ The heterogeneity of PANSS total score assessed by I^2^ decreased from 93% to 76% after removing one outlying study;^\[[@ref15]\]^ in addition, the significance disappeared, which could be due to the decreased sample size thereby reducing the power detecting significant results. The previous meta-analyses^\[[@ref24]\]^ supported our interpretation that adjunctive ECT can be an efficacious treatment for improving total psychopathology in schizophrenia patients. Agitation poses a significant challenge in the treatment of schizophrenia.\[[@ref1]\] However, the current meta-analysis of 7 relatively low quality RCTs showed that both ECT alone and the ECT-AP combination are ineffective treatments for agitation in 480 Chinese schizophrenia patients. This meta-analysis indicates that other symptoms (e.g. hallucination, delusion, etc.) maybe respond better to ECT when compared with agitation related outcomes in schizophrenia patients.
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![](sap-29-1-i001.jpg) **Notice for soliciting papers for the 14^th^ academic conference of the Chinese Society of Neuroscience & Psychiatry (CSNP)**

**"The 14^th^ annual academic conference of the Chinese Society of Neuroscience & Psychiatry"**, which is hosted by CSNP, and undertaken by Mental Health Center of Shanghai Jiao Tong University's medical school and Shandong Mental Health Center, will be held in the Luneng Hilton Hotel in Jinan, Shandong, from 29^th^ June to 1^st^ July, 2017.

The present society welcomes paper submissions and conference participations. The conference affair group accepts abstracts (objectives, methods, results and conclusions) under 1000 words. The website used for paper submissions and registrations is <http://61.147.124.137:8088/2017/default.aspx.> The academic committee of this conference will review papers and select high quality reports for presentation at the conference. We look forward to your participation and support! The deadline for paper submission is 1^st^ June, 2017.

We welcome colleagues from all over China and abroad to participate in this conference held in scenic Jinan. We are looking forward to a lively discussion on developments in the field.

**Dates:** 29^th^ June to 1^st^ July, 2017 (check in on 29^th^ June)

**Address:** Luneng Hilton Hotel in Jinan, Shandong, No.2888 South Erhuan Lu, Central District in Jinan

**Cost arrangement:** The registration fee, travel fee and accommodation fee are at your own expense. The registration fee is 1000 yuan (Shandong representatives and graduate students with student IDs can pay half of the registration fee). The accommodation fee from 30^th^ June to 1^st^ July 2017 is 500 yuan per standard room.

**Contact:** Ruizhi Mao 18221768225

**E-mail:** <csnpmeeting@163.com>

**Chinese Society of Neuroscience & Psychiatry**

**4^th^ February 2017**

**Erratum**

Li HB, Wang Y, Jiang J, Li W, Li CB. Effects of transcranial direct current stimulation (tDCS) for auditory hallucinations: A systematic review. *Shanghai Arch Psychiatry.* 2016; **28**(6):301-308. doi: http://dx.doi.org/10.11919/j.issn.1002-0829.216121

In the [Figure 1](#fig001){ref-type="fig"} (identification of included studies) of the paper, the number in the first box "304 potential articles published before 13 February 2016 were identified..." should be "432 potential articles published before 13 February 2016 were identified...". This change was been made to the online version on the *Shanghai Archives of Psychiatry* website as of 10 Jan, 2017.
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![Add-on ECT to antipsychotics for agitation in schizophrenia: forest plot for the Positive and Negative Syndrome Scale (PANSS) total score at 7 and 14 days as well as PANSS agitation and excitement subscore at 14 days](sap-29-1-g004){#fig004}

###### 

Characteristics of the RCTs

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                     N     -Blinding\          Trial\           Country   Patients:\                    Age^[a](#table1-tfn1){ref-type="table-fn"}^: years (range)   Sex: Male (%)   Interventions: APs (mg/day); ECT (sessions)   Outcomes      Jadad score
                                                  -Setting (%)        Duration (wks)             -Diagnosis\                                                                                                                                                            
                                                                                                 -Criteria\                                                                                                                                                             
                                                                                                 -Illness duration (yrs)                                                                                                                                                
  ----------------------------------------- ----- ------------------- ---------------- --------- ----------------------------- ------------------------------------------------------------ --------------- --------------------------------------------- ------------- -------------
  **ECT alone vs. APs (trials=4, n=240)**                                                                                                                                                                                                                               

  Guo et al 2009^\[[@ref10]\]^              60    -Open label\        2                China     -Sz\                          32.5\                                                        n=24\           1\. HAL (10-20); n=30;\                       PANSS;\       1
                                                  -Inpatients (100)                              -CCMD-3\                      (18-50)                                                      (40%)           2. ECT (8); n=30                              CGI;\         
                                                                                                 -Illness duration: 0.66                                                                                                                                  TESS          

  Shen et al 2011^\[[@ref11]\]^             90    -Open label\        2                China     -Sz\                          32.8\                                                        n=46\           1\. OLA (5-20); n=30;\                        PANSS; TESS   2
                                                  -Inpatients (100)                              -CCMD-3 (first episode)\      (18-59)                                                      (51%)           2. ECT (etomidate, 6); n=30;\                               
                                                                                                 -Illness duration: 0.17                                                                                    3. ECT (propofol, 6); n=30                                  

  Yuan et al 2012^\[[@ref12]\]^             30    -Open label\        2                China     -Sz\                          31.9\                                                        n=13\           1\. HAL (10-60); n=15;\                       PANSS; TESS   2
                                                  -Inpatients (100)                              -CCMD-3\                      (NR)                                                         (43%)           2. ECT (6); n=15                                            
                                                                                                 -Illness duration: 9.1 days                                                                                                                                            

  Li 2015^\[[@ref14]\]^                     60    -Open label\        8                China     -Sz\                          32.4\                                                        n=34\           1\. CLZ (50-75); n=30;\                       BPRS; TESS    2
                                                  -Inpatients (100)                              -CCMD-3\                      (20-60)                                                      (57%)           2. ECT (6-12); n=30                                         
                                                                                                 -Illness duration: NR                                                                                                                                                  

  **ECT+ APs vs. APs (trials=3, n=240)**                                                                                                                                                                                                                                

  Yang et al 2005^\[[@ref9]\]^              60    -Open label\        8                China     -Sz\                          NR.\                                                         n=38\           1\. CLZ (445); n=30;\                         PANSS; TESS   2
                                                  -Inpatients (100)                              -CCMD-3 (refractory)\         (NR)                                                         (63%)           2. CLZ (436) + ECT (6-12); n=30                             
                                                                                                 -Illness duration: 6.1                                                                                                                                                 

  Peng et al 2014^\[[@ref13]\]^             80    -Open label\        2                China     -Sz\                          32.5\                                                        n=55\           1\. RIS (5.4); n=40;\                         PANSS; TESS   3
                                                  -Inpatients (100)                              -ICD-10\                      (NR)                                                         (69%)           2. RIS (5.2) + ECT (6-8); n=40                              
                                                                                                 -Illness duration: 3.8                                                                                                                                                 

  Pan 2015 ^\[[@ref15]\]^                   100   -Open label\        8                China     -Sz\                          43.5\                                                        n=80\           1\. AP^b^ (NR); n=50;\                        PANSS;        2
                                                  -Inpatients (100)                              -ICD-10\                      (22-63)                                                      (80%)           2. AP^b^ (NR) + ECT (8-12); n=50                            
                                                                                                 -Illness duration: 5.3                                                                                                                                                 
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^weighted mean

^b^did not report the detailed use of antipsychotics.

APs = antipsychotics; BPRS = Brief Psychiatric Rating Scale; CLZ = Clozapine; CGI = Clinical Global Impression; CCMD-3 = The Chinese Classification of Mental Disorders 3^th^ edition; ECT = Electroconvulsive therapy; HAL = Haloperidol; ICD-10 = International Classification of Diseases, 10^th^ edition; NR = not report; OLA = Olanzapine; PANSS = Positive and Negative Syndrome Scale; RCT = randomized controlled trial; RIS = Risperidone; Sz = schizophrenia; TESS = Treatment Emergent Symptom Scale; yrs = years; wks = weeks.

###### 

Evaluation of risk of bias in the seven included studies

  study                            sequence generation   allocation sequence concealment   blinding of participants and personnel   blinding of outcome assessment   incomplete outcome data   selective outcome reporting   other potential threats to validity
  -------------------------------- --------------------- --------------------------------- ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -------------------------------------
  Pan 2015 ^\[[@ref15]\]^          unclear               high                              high                                     high                             low                       unclear                       unclear
  Peng et al 2014 ^\[[@ref13]\]^   low                   high                              high                                     high                             low                       high                          unclear
  Yang et al 2005 ^\[[@ref9]\]^    unclear               high                              high                                     high                             low                       unclear                       unclear
  Guo et al 2009^\[[@ref10]\]^     unclear               high                              high                                     high                             low                       unclear                       unclear
  Li 2015 ^\[[@ref14]\]^           unclear               high                              high                                     high                             low                       unclear                       unclear
  Yuan et al 2012 ^\[[@ref12]\]^   unclear               high                              high                                     high                             unclear                   unclear                       unclear
  Shen et al 2011 ^\[[@ref11]\]^   unclear               high                              high                                     high                             unclear                   unclear                       unclear

###### 

GRADE Analyses for main primary and secondary outcomes: ECT for agitation in schizophrenia

  Outcomes                     N (arms)   Risk of bias                                      Inconsistency                                     Indirectness   Imprecision   Publication bias                                  Large effect                                         Overall quality of evidence^[a](#table3-tfn1){ref-type="table-fn"}^
  ---------------------------- ---------- ------------------------------------------------- ------------------------------------------------- -------------- ------------- ------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------------------------
  **ECT alone vs. APs**                                                                                                                                                                                                                                                           
  PANSS total score            90(2)      Serious^[b](#table3-tfn2){ref-type="table-fn"}^   No                                                No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Low
  PANSS excitement sub-score   180(4)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   No                                                No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Low
  PANSS agitation sub-score    30(1)      Serious^[b](#table3-tfn2){ref-type="table-fn"}^   No                                                No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Low
  Headache                     180(3)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   No                                                No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   Very large^[e](#table3-tfn5){ref-type="table-fn"}^   High
  Akathisia                    180(3)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   No                                                No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Low
  **ECT+ APs vs. APs**                                                                                                                                                                                                                                                            
  PANSS total score            240(3)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   Serious^[c](#table3-tfn3){ref-type="table-fn"}^   No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Very Low
  PANSS excitement sub-score   140(2)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   Serious^[c](#table3-tfn3){ref-type="table-fn"}^   No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Very Low
  PANSS agitation sub-score    140(2)     Serious^[b](#table3-tfn2){ref-type="table-fn"}^   Serious^[c](#table3-tfn3){ref-type="table-fn"}^   No             No            Serious^[d](#table3-tfn4){ref-type="table-fn"}^   No                                                   Very Low

APs = antipsychotics; ECT = Electroconvulsive therapy; GRADE = grading of recommendations assessment, development, and evaluation; PANSS = Positive and Negative Syndrome Scale

^a^GRADE Working Group grades of evidence: High quality=further research is very unlikely to change our confidence in the estimate of effect. Moderate quality=further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality=further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality=we are very uncertain about the estimate.

^b^All studies reported as having a serious bias used a open label method, only mentioned random allocation without describing the method and withdrawal from the study.

^c^All studies reported as having a serious inconsistency had I^2^\> 50%.

^d^For continuous outcomes, N \< 400; For dichotomous outcomes, N\<300.

^e^The results of meta-analytic outcomes: RR\>5 or \<0.2

[^1]: **Review registration number:** CRD42014006689

[^2]: ^\#^These authors equally contributed to the work.
